Use of the Absorb bioresorbable vascular scaffold (BVS, Abbott Vascular) is associated with an increased risk of definite or probable scaffold thrombosis at 1 year and beyond, as well as increased ...

In patients with very long coronary lesions, use of Absorb BVS (Abbott Vascular) is associated with a high rate of TLF at 1 year, driven by MI and clinically driven TLR, according to a subanalysis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. New 1-year data from the ASSURE registry demonstrate ...

Please provide your email address to receive an email when new articles are posted on . An everolimus-eluting bioresorbable vascular scaffold appears to be safe and effective in patients with diabetes ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). By way of ...

Patients implanted with a bioresorbable vascular scaffold (BVS) have higher rates of target-vessel myocardial infarction and device thrombosis at 3 years than patients treated with everolimus-eluting ...

Bioresorbable vascular scaffolds (BVS) are the latest innovation in the field of coronary interventions and are emerging as a promising treatment for patients with coronary artery stenoses Available ...